Literature DB >> 2946973

The topography of plaques and tangles in Down's syndrome patients of different ages.

D M Mann, P O Yates, B Marcyniuk, C R Ravindra.   

Abstract

The topographical distribution of senile plaques and neurofibrillary tangles has been investigated in 12 patients with Down's syndrome ranging from 31 to 65 years of age. No plaques or tangles whatsoever were seen in the brain of the 31-year-old patient. The nine patients over 53 years of age, showed a similar pathological picture in which there were numerous mature plaques in all areas of cerebral cortex, hippocampus and amygdala and numerous tangles in these areas and in subcortical structures such as nucleus basalis, locus caeruleus, dorsal raphe, ventral tegmental area, substantia nigra, olfactory bulb and tracts. In the other two patients aged 37 and 51 years, an intermediate pathological picture was seen in which primitive plaques predominated within the cortex, with numerous mature plaques in hippocampus and amygdala. In the 37-year-old patient, tangles were numerous in the entorhinal cortex, but much less common in hippocampus and amygdala, rare in cerebral cortex and absent in the subcortical areas, olfactory bulbs and tracts. A similar pattern was seen in the 51-year-old patient though here some cells in the subcortex were also affected. These observations suggest that the primary focus of plaque and tangle formation in Down's syndrome may be in amygdala, entorhinal cortex and hippocampus, with a 'spreading out' to subsequently involve all areas of cortex, certain subcortical regions and the olfactory bulbs and tracts. It appears unlikely that the olfactory bulbs and tracts provide a portal of entry for any pathogenic agent that may be responsible for inducing plaque and tangle formation within the rest of the brain.

Entities:  

Mesh:

Year:  1986        PMID: 2946973     DOI: 10.1111/j.1365-2990.1986.tb00053.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  38 in total

1.  Dementia diagnostic criteria in Down syndrome.

Authors:  Rory Sheehan; Amanda Sinai; Nick Bass; Pippa Blatchford; Ingrid Bohnen; Simon Bonell; Ken Courtenay; Angela Hassiotis; Therese Markar; Jane McCarthy; Kamalika Mukherji; Asim Naeem; Dimitrios Paschos; Natalia Perez-Achiaga; Vijaya Sharma; David Thomas; Zuzana Walker; Andre Strydom
Journal:  Int J Geriatr Psychiatry       Date:  2014-11-03       Impact factor: 3.485

2.  Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome.

Authors:  Brian E Powers; Ramon Velazquez; Christy M Kelley; Jessica A Ash; Myla S Strawderman; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Brain Struct Funct       Date:  2015-12-30       Impact factor: 3.270

3.  Astrocytes in Alzheimer's disease gray matter express alpha 1-antichymotrypsin mRNA.

Authors:  J M Pasternack; C R Abraham; B J Van Dyke; H Potter; S G Younkin
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

4.  Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: a model of Down syndrome.

Authors:  Chie Harashima; David M Jacobowitz; Jassir Witta; Rosemary C Borke; Tyler K Best; Richard J Siarey; Zygmunt Galdzicki
Journal:  J Comp Neurol       Date:  2006-02-10       Impact factor: 3.215

Review 5.  [Current immune therapy for Alzheimer's disease].

Authors:  T Grimmer; R Perneczky; A Kurz
Journal:  Nervenarzt       Date:  2008-07       Impact factor: 1.214

Review 6.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

Review 7.  The role of the amyloid protein precursor (APP) in Alzheimer's disease: does the normal function of APP explain the topography of neurodegeneration?

Authors:  D H Small
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

8.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

9.  Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice.

Authors:  Jessica A Ash; Ramon Velazquez; Christy M Kelley; Brian E Powers; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Neurobiol Dis       Date:  2014-06-14       Impact factor: 5.996

10.  Maternal choline supplementation programs greater activity of the phosphatidylethanolamine N-methyltransferase (PEMT) pathway in adult Ts65Dn trisomic mice.

Authors:  Jian Yan; Stephen D Ginsberg; Brian Powers; Melissa J Alldred; Arthur Saltzman; Barbara J Strupp; Marie A Caudill
Journal:  FASEB J       Date:  2014-06-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.